Bioceres Crop Solutions Corp.

to pass the conference over to our host, Paula Savanti, Head of Investor Relations.

You may go ahead. Thank you. Good afternoon and welcome. Thank you, everyone, for joining our call. Presenting today during the call will be Federico Trucco, our Chief Executive Officer, and Enrique Lopez de Cube, our Chief Financial Officer. Both will be available for the Q&A session. Before we proceed, I would like to make the following safe harbor statement. Today's call will contain forward-looking statements and I refer you to the forward-looking statement section of today's earnings release and presentation, as well as the recent filings with the SEC. We assume no obligation to update or revise any forward-looking statements to reflect new or changed circumstances. This conference call is being webcast and the webcast link is available at Biocera's Crop Solutions Investor Relations website. At this time, I will turn the call over to our CEO, Federico Trucco. Thank you.

Thank you, Paula. And thanks to everyone that is joining us today in our fourth quarter and full fiscal year 2023 earnings call. Good afternoon. Please turn to slide three for a brief overview of the highlights of these calls. While fiscal year 2023 was challenging, mostly due to external conditions, it was one during which we proved the resiliency of our organization, adjusting business plans to ensure we continue to outperform. So what have we accomplished in fiscal 23? First, we continue to grow at double digit rates. And as you will see in a minute, this growth comes after a record year in fiscal 22. Our growth in profitability as measured by our adjusted EBITDA, which grew by 31% to over 81 million, was even more impressive when you know that we are not longer excluding HB4 inventory ramp-up costs as we did in prior years, and that we are fully integrating pro-farm, a business that was not profitable at the time of our acquisition a year ago. Revenues in this quarter were flat compared to last year and 9% lower on a pro forma basis, while the gross profit contribution was kept steady, indicating an expansion in profitability for the products that were sold. An important milestone for the quarter is that the legacy ProPharm part of our business became a big deposit on an LTM basis for the first time, which is one of the objectives we proposed for the first 12 months. So congratulations are in order to the ProPharm team for their sustained efforts in reaching this goal. On the HB4 wheat front, we have grown revenues by 28% in the quarter, But what is more important is that we grew our multiplier network by eight folds, which is critical in two ways. First, in that it allows us to transfer inventory ramp-up costs to others and thus achieve a leaner working capital model. And also, in that it expands our commercial footprint beyond the Generation HP4 Identity Preserve program, which is a key step towards meeting our fiscal year 24 guidance in this crop. On the HB4 soy front, and more specifically on the HB4 soy downstream side, we announced an agreement with Mulex Science, a provider of soy derived food ingredients, to supply them with approximately 20,000 tons of ESG linked HB4 beans something we'll do jointly with our Generation HP4 farmers, monetizing data and traceability premiums for the first time since starting with this IP program. Finally, our agreement with Corteva Seed Applied Technologies for MBI 306 will allow us to at least double the size of our joint business in the European region and further validates our position as a leading provider of biological seed care solutions to top players in our industry. Before I turn the call over to Enrique for a detailed discussion on our financial performance, please turn to slide four so that we can put this year's growth in perspective. It's certainly not the same to show growth after a down year than to do so after a record year, and more so in one in which we had to face historical drought in our main market, the industry-wide after-party effects of inventory resetting in the United States and Brazil, our second and third largest markets, and the added challenge of integrating an existingly unique business like Marron Bio Innovations, now Profarm, which was still pre-profit at the time of the acquisitions. So to see this doubling in revenues over the last two years and growing more than 60% in adjusted profitability for the same time period is indeed very impressive and a result that we are very proud of. Enrique?